(Total Views: 734)
Posted On: 06/21/2020 1:20:47 PM
Post# of 153911
“It is still foolish to short a "trillion dollar molecule".
Leronlimab is not currently a trillion dollar molecule nor it will be for many years, if ever. The trillion dollar mark will take numerous clinically proven indications and those trials take years.
In the meantime, CYDY is a short target like any other biotech that makes gains, or really any stock that makes gains and is set to consolidate. CYDY ran to the 3.60 range and pulled back all the way to what, $2.30 or so? And then rebounded to the $3 range. It’s going to happen.
Leronlimab is not currently a trillion dollar molecule nor it will be for many years, if ever. The trillion dollar mark will take numerous clinically proven indications and those trials take years.
In the meantime, CYDY is a short target like any other biotech that makes gains, or really any stock that makes gains and is set to consolidate. CYDY ran to the 3.60 range and pulled back all the way to what, $2.30 or so? And then rebounded to the $3 range. It’s going to happen.
(0)
(0)
